Abbvie uses Lifebit's platform to advance the search for new treatments for common chronic illnesses through population genomics research.

Ionis Pharmaceuticals use the Lifebit platform and a combination of deep phenotypic data and high-quality whole-genome sequencing to improve the understanding of fundamental disease mechanisms. This strategy has the potential to greatly accelerate the drug development process by translating targets into therapies faster.

J&J uses Lifebit's platform to seek to understand differences in patient responses in autoimmune disorders to make it easier to target more specific patient subpopulations that could lead to the development of new treatment drugs.

The Lifebit platform empowers GSK to assess variability among patients with conditions including heart failure and liver disease and gain a deeper understanding of illness severity and symptoms. It is intended to make it easier to identify more focused patient subgroups, which could potentially allow for the advancement of particular therapeutic medicines in particular patient subgroups.